Metaiodobenzylguanidine and Neuroblastoma

Abstract

Neuroblastoma is the most common extracranial solid tumor in childhood, arising in the sympathetic nervous system, metastatic in half of the patients at diagnosis, with bone and bone marrow as the most frequent sites involved. Most neuroblastomas express the noradrenalin transporter molecule and take up metaiodobenzylguanidine (mIBG), providing a sensitive and specific method of assessing primary tumor and metastatic sites (soft tissue, bone marrow, and bone) when labeled with iodine-123, both at diagnosis, for staging, and as a prognostic factor for evaluation of response to therapy, especially when a semiquantitative scoring method is used. mIBG labeled with iodine-131 has demonstrated activity for targeted therapy of neuroblastoma in both relapsed and newly diagnosed patients, and is being used in clinical trials to optimize treatment of high-risk patients.

Keywords

neuroblastoma - mIBG - treatment - scoring

• References

• 1 London WB, Castleberry RP, Matthay KK , et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23 (27) 6459-6465
• 2 Olivier P, Colarinha P, Fettich J , et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30 (5) B45-B50
• 3 Piccardo A, Lopci E, Conte M , et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012; 39 (1) 57-71
• 4 Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50 (8) 1237-1243
• 5 Leung A, Shapiro B, Hattner R , et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38 (9) 1352-1357
• 6 Bouvier JF, Philip T, Chauvot P , et al. Pitfalls and solutions in neuroblastoma diagnosis using radioiodine MIBG: our experience about 50 cases. Prog Clin Biol Res 1988; 271: 707-720
• 7 Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med 1995; 25 (3) 235-30
• 8 Taggart DR, Han MM, Quach A , et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27 (32) 5343-5349
• 9 Seo Y, Gustafson WC, Dannoon SF , et al. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol 2012; 14 (6) 735-742
• 10 Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37 (9) 1464-1468
• 11 Melzer HI, Coppenrath E, Schmid I , et al. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38 (9) 1648-1658
• 12 Matthay KK, Shulkin B, Ladenstein R , et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102 (9) 1319-1326
• 13 Matthay KK, Edeline V, Lumbroso J , et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21 (13) 2486-2491
• 14 Ady N, Zucker JM, Asselain B , et al. A new 123I-MIBG whole body scan scoring method—application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A (2) 256-261
• 15 Messina JA, Cheng SC, Franc BL , et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006; 47 (7) 865-874
• 16 Yanik GA, Levine JE, Matthay KK , et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20 (8) 2142-2149
• 17 Suc A, Lumbroso J, Rubie H , et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996; 77 (4) 805-811
• 18 Frappaz D, Bonneu A, Chauvot P , et al; The SFOP Group. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. Med Pediatr Oncol 2000; 34 (4) 237-241
• 19 Frappaz D, Philip T, Chauvin F , et al. [Systematic screening for neuroblastoma]. Arch Pediatr 1995; 2 (10) 1016-1018
• 20 Perel Y, Conway J, Kletzel M , et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21 (1) 13-18
• 21 Katzenstein HM, Cohn SL, Shore RM , et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22 (19) 3909-3915
• 22 Ladenstein R, Philip T, Lasset C , et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16 (3) 953-965
• 23 Gaze MN, Wheldon TE, O'Donoghue JA , et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A (2) 252-256
• 24 Vik TA, Pfluger T, Kadota R , et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52 (7) 784-790
• 25 Matthay KK, Tan JC, Villablanca JG , et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24 (3) 500-506
• 26 Kang TI, Brophy P, Hickeson M , et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003; 25 (10) 769-773
• 27 Hoefnagel CA, De Kraker J, Valdés Olmos RA, Voûte PA. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (4) (Suppl. 01) 61-64
• 28 Riad R, Kotb M, Omar W , et al. Role of 131-I MIBG therapy in the treatment of advanced neuroblastoma. J Egypt Natl Canc Inst 2009; 21 (1) 51-58
• 29 Howard JP, Maris JM, Kersun LS , et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005; 44 (3) 232-239
• 30 Giammarile F, Borson-Chazot F. [Neuroendocrine tumours treated with mIBG and radiolabeled peptides]. Pathol Biol (Paris) 2006; 54 (3) 130-136
• 31 Matthay KK, Quach A, Huberty J , et al. Iodine-131—metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27 (7) 1020-1025
• 32 Brodeur GM, Pritchard J, Berthold F , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (8) 1466-1477
• 33 Monclair T, Brodeur GM, Ambros PF , et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2) 298-303